Clinical bottom line
Optimizing management of hepatic encephalopathy (HE) in cirrhotic patients requires a multifaceted approach emphasizing nutritional support, identification and treatment of precipitating factors, and careful medication management. Nutritional optimization, including adequate protein intake and correction of micronutrient deficiencies, is critical to improve cognitive outcomes and reduce HE episodes. Emerging evidence suggests proton pump inhibitors may not increase HE risk as previously thought. Multidisciplinary care integrating nutrition, hepatology, and neurocognitive assessment is essential for improving patient outcomes (Mendez-Guerrero et al., 2024; Chadalavada et al., 2010).
What the evidence shows
Mendez-Guerrero et al. (2024) provide a comprehensive review underscoring the importance of tailored nutritional strategies in cirrhosis, highlighting that adequate caloric and protein intake supports muscle mass preservation and ammonia detoxification, thus mitigating HE severity. They advocate for regular nutritional assessments and individualized care plans.
Chadalavada et al. (2010) emphasize that protein restriction is no longer recommended; instead, maintaining 1.2–1.5 g/kg/day of protein is beneficial. They also discuss the role of branched-chain amino acids and micronutrients in HE management.
Teixera Corda et al. (2017) challenge prior concerns about proton pump inhibitors (PPIs) increasing HE risk, reporting no significant association between PPI use and HE incidence in cirrhotic patients, suggesting PPIs can be used judiciously when indicated.
Ingustu et al. (2023) review postoperative cognitive dysfunction in cirrhosis, highlighting the need for perioperative cognitive monitoring and tailored anesthetic approaches to reduce HE exacerbations.
Lesmana et al. (2025) update management guidelines for acute variceal bleeding, a common precipitant of HE, underscoring prompt hemostasis and supportive care to prevent HE worsening.
Caveats and uncertainty
Optimal nutritional regimens vary with disease severity and comorbidities; evidence for specific supplements remains limited.
Data on long-term effects of PPIs in cirrhosis are mixed; cautious use is advised.
Cognitive assessment tools for HE vary in sensitivity and specificity; standardized protocols are lacking.
Management of covert HE remains challenging due to subtle clinical presentations.
Further research is needed on integrated care models and novel therapeutics.
How this may change practice
Clinicians should prioritize comprehensive nutritional evaluation and avoid unnecessary protein restriction in HE management.
PPIs should not be withheld solely due to HE concerns but used based on clear indications.
Routine cognitive screening may facilitate earlier HE detection and intervention.
Multidisciplinary teams including nutritionists, hepatologists, and neuropsychologists can optimize care.
Awareness of precipitating factors such as variceal bleeding and infections remains critical for prevention.